LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Начало・Списък с акции・Editas Medicine Inc

Editas Medicine Inc

Затворен

СекторЗдравеопазване

1.75 4.79

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.74

Максимум

1.76

Ключови измерители
By Trading Economics
Приходи	28M -25M
Продажби	4M 7.5M
Марж на печалбата	-332.984
Служители	246
EBITDA	27M -22M

Препоръки
By TipRanks
Препоръки	Продай
12-месечна прогноза	+127.27% upside

Дивиденти
By Dow Jones
Следващи печалби	4.03.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-98M 177M
Предишно отваряне	-3.04
Предишно затваряне	1.75

Настроения в новините

By Acuity

50%

127 / 351 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

1.33 / 1.54 Подкрепа & съпротива

Editas Medicine Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

15.02.2026 г., 23:21 ч. UTC

Придобивния, сливания и поглъщания

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

15.02.2026 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

15.02.2026 г., 23:40 ч. UTC

Пазарно говорене

Gold Falls on Possible Position Adjustments -- Market Talk

15.02.2026 г., 23:06 ч. UTC

Печалби

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

15.02.2026 г., 23:04 ч. UTC

Печалби

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

15.02.2026 г., 23:04 ч. UTC

Печалби

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

15.02.2026 г., 23:01 ч. UTC

Печалби

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

15.02.2026 г., 23:01 ч. UTC

Печалби

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

15.02.2026 г., 22:53 ч. UTC

Придобивния, сливания и поглъщания

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

15.02.2026 г., 22:53 ч. UTC

Придобивния, сливания и поглъщания

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

15.02.2026 г., 22:52 ч. UTC

Придобивния, сливания и поглъщания

Qube Shareholders to Receive A$5.20/Share in Cash

15.02.2026 г., 22:52 ч. UTC

Придобивния, сливания и поглъщания

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

15.02.2026 г., 22:22 ч. UTC

Придобивния, сливания и поглъщания

BlueScope CEO Tania Archibald Speaking on a Call With Media

15.02.2026 г., 22:17 ч. UTC

Придобивния, сливания и поглъщания

BlueScope CEO: Stresses Whyalla Project Would Have to Make Sense to Shareholders

15.02.2026 г., 22:16 ч. UTC

Придобивния, сливания и поглъщания

BlueScope CEO: Some Job Cuts Inevitable to Ensure Company is Competitive

15.02.2026 г., 22:14 ч. UTC

Придобивния, сливания и поглъщания

BlueScope CEO: Higher Returns Tied to End of Capital Investment Program

15.02.2026 г., 22:14 ч. UTC

Придобивния, сливания и поглъщания

BlueScope Steel CEO: Higher Returns After Rebuffed Takeover Bid a 'Natural Coincidence'

15.02.2026 г., 20:48 ч. UTC

Печалби

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

15.02.2026 г., 20:47 ч. UTC

Печалби

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

15.02.2026 г., 20:46 ч. UTC

Печалби

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

15.02.2026 г., 20:45 ч. UTC

Печалби

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

15.02.2026 г., 20:44 ч. UTC

Печалби

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

15.02.2026 г., 20:44 ч. UTC

Печалби

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

15.02.2026 г., 20:43 ч. UTC

Печалби

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

15.02.2026 г., 20:42 ч. UTC

Печалби

BlueScope Net Debt A$2.2 Million at Dec. 31

15.02.2026 г., 20:42 ч. UTC

Печалби

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

15.02.2026 г., 20:41 ч. UTC

Печалби

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

15.02.2026 г., 20:40 ч. UTC

Печалби

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

15.02.2026 г., 20:40 ч. UTC

Печалби

BlueScope 1H Sales Revenue From Continuing Ops A$8.22 Billion, Up 4% On-Year

15.02.2026 г., 20:39 ч. UTC

Печалби

BlueScope Intends to Spend A$310 Million on Buyback, Or Other Returns if Share Repurchases Limited

Сравнение с други в отрасъла

Ценова промяна

Editas Medicine Inc Прогноза

Ценова цел

By TipRanks

127.27% нагоре

12-месечна прогноза

Среден 4 USD 127.27%

Висок 4 USD

Нисък 4 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Editas Medicine Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Продай

2 ratings

Купи

Задържане

Продай

Според 2 анализатори, дали борсови рейтинги на Editas Medicine Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.33 / 1.54Подкрепа & съпротива

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

There are no events.

Настроение

By Acuity

127 / 351 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.